Today is an opportune moment to mention STAT's next live event in San Francisco on May 19. I will be chatting on stage with $INSM CEO Will Lewis and $BBIO CEO Neil Kumar. Full agenda and registration here: https://t.co/YtXTTuz1Nv
Third and final $PFE tafamidis patent lawsuit dismissed. $BBIO up
$BBIO $ALNY moving higher on apparently good news re: Pfizer's tafamidis patent defense. If you have access to Umer Raffat's research, he has all the details.
$IBRX $12B market cap, on par w $BMRN, just behind $BBIO $NBIX and larger than $JAZZ $MDGL Your 2026 biotech meme stock...
BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase 3 success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde
$BBIO Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 https://t.co/R6UndoW0DS
BridgeBio $BBIO study data on drug for rare form of muscular dystrophy could set up approval https://t.co/S4LRPEh4sb via @Jasonmmast
